PipelineReview.com3h
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
“We look forward to advancing CTIM-76 toward target dose levels in 2025,” commented Claudio Dansky Ullmann, M.D., Chief Medical Officer of Context.
PipelineReview.com3h
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
INCHEON, South Korea I January 14, 2025 I Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug ...
PipelineReview.com3h
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
WHIPPANY, NJ, USA I January 14, 2025 I On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in ...
PipelineReview.com20h
Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones
In conjunction with the Series C financing, Umoja’s Board of Directors is pleased to welcome Campbell Murray, M.D., a Senior Adviser at Double Point Ventures, as a new Board member.
PipelineReview.com18h
FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma
BERLIN, Germany I January 14, 2025 I Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, ...